In fact, the phosphorylation of CrkL at Y207 is considered an indicator of cancer remission in Chronic Myeloid Leukemia patients after imatinib treatment12, and previously was the only identified phospho-site known to regulate CrkL activity. Here, CRKL is linked to cancer.